Related Experiment Videos
Chemoimmunotherapy with Krestin in acute leukemia
The Tokai Journal of Experimental and Clinical Medicine
|April 1, 1981
Summary
Immunotherapy with Krestin significantly prolonged remission and survival durations in acute leukemia patients. This chemoimmunotherapy approach also enhanced cell-mediated immunity compared to chemotherapy alone.
Area of Science:
- Oncology
- Immunology
Background:
- Acute leukemia poses significant treatment challenges, necessitating improved maintenance therapies.
- Optimizing remission duration and patient survival are critical goals in acute leukemia management.
Purpose of the Study:
- To evaluate the efficacy of Krestin immunotherapy as maintenance therapy in acute leukemia.
- To determine if Krestin can prolong complete remission and survival durations.
Main Methods:
- Randomized controlled trial comparing chemotherapy with chemoimmunotherapy (Krestin + chemotherapy).
- Patients with acute leukemia were allocated to either the chemotherapy or chemoimmunotherapy group.
- Assessment of complete remission rates, duration of remission, survival time, and cell-mediated immunity.
Main Results:
- The chemoimmunotherapy group demonstrated longer median durations of complete remission and survival compared to the chemotherapy group.
- A higher complete remission rate was observed in the second induction phase for the chemoimmunotherapy group.
- Cell-mediated immunity showed enhancement in the chemoimmunotherapy group, but not in the chemotherapy group.
Conclusions:
- Krestin administration as maintenance therapy is beneficial for prolonging remission and survival in acute leukemia patients.
- Chemoimmunotherapy with Krestin offers a potential advantage over standard chemotherapy for acute leukemia.
- Enhanced cell-mediated immunity may contribute to the improved outcomes observed with Krestin therapy.